Concepedia

Daniel Lu

DL

Statistics

Publications

10

Citations

394

H-Index

10

Active since

2018

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

University of British Columbia

Cornell University

BC Cancer Agency

Weill Cornell Medicine

Daniel Lu is an author at Memorial Sloan Kettering Cancer Center specializing in lung cancer, tumor biology, and cell biology.

ORCID

Top concepts

Publications per year

2018–2025

10

Publications

10

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer

Ken Suzawa, Michael Offin, Daniel Lu et al. · Clinical Cancer Research · 2018 · 115 citations

Epithelial tumor suppressor ELF3 is a lineage-specific amplified oncogene in lung adenocarcinoma

Katey S.S. Enfield, Erin A. Marshall, Kevin W. Ng et al. · Nature Communications · 2019 · 69 citations · Full text

Acquired <i>MET</i> Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in <i>EGFR</i> -Mutated Lung Cancer

Ken Suzawa, Michael Offin, Adam J. Schoenfeld et al. · JCO Precision Oncology · 2019 · 54 citations · Full text

, , +15

The effect of Bruton's tyrosine kinase (<scp>BTK</scp>) inhibitors on collagen‐induced platelet aggregation, <scp>BTK</scp>, and tyrosine kinase expressed in hepatocellular carcinoma (<scp>TEC</scp>)

Jun Chen, Taisei Kinoshita, Tarikere Gururaja et al. · European Journal Of Haematology · 2018 · 42 citations · Full text

Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4

Jack Calder, Amy Nagelberg, Jennifer Luu et al. · Oncogenesis · 2021 · 26 citations · Full text

1–5 of 10